title: Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.
abstract: The National Cancer Institute's (NCI) chemoprevention plan employs a strategy of basic and epidemiologic studies, followed by a structured preclinical process to bring chemopreventive agents into clinical testing. The field of chemoprevention is progressing rapidly and has reached the point where a coordinated international approach for large-scale trials would be useful. At present, NCI is sponsoring nine large trials (over $1 million per year per trial); in addition, nine agents are in phase I or II clinical testing. A number of these agents should be ready soon for phase III testing. Resources required for large-scale trials compel greater attention to efficient trial design, concept development and review, priority setting, management, budgeting, and collaboration.
authors.affiliation: Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 29892.
authors.forename: K A
authors.initials: KA
authors.lastname: Johnson
authors.forename: L G
authors.initials: LG
authors.lastname: Ford
authors.forename: B
authors.initials: B
authors.lastname: Kramer
authors.forename: P
authors.initials: P
authors.lastname: Greenwald
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000517:prevention & control*; D012106:Research; D014481:United States
chemical_list: D000970:Antineoplastic Agents